CN

Lupin

Lupin is an innovation led transnational pharmaceutical company with presence in over 100 countries and turnover of US $ 2.5 billion. We focus on development of difficult to develop, specialty and niche generics in the fields of CNS, anti-infectives, respiratory, CVS, urology, pain and diabetes. With continued investments towards internalizing technology platforms in the fields of biotechnology, complex/long acting injectables, inhalation, Lupin is well positioned to become a global pharmaceutical powerhouse with a broad specialty portfolio. Several inhalation products (MDI/DPIs) have already been filed globally and first filings for Europe to begin in the very near future. Development of complex injectables in the diabetes, oncology, CNS completed and global filings began in 2019. Lupin has an enviable quality and delivery track record. We consistently achieve an OTIF of 95% or more. For more information, log on to: www.lupin.com

Advantage products:

Product Name Category Characteristic & Application CDMF status
Levetiracetam
I
Ezetimibe
I
Levothyroxine sodium
Plan to declare
Lisinopril
Plan to declare
Pirfenidone
I
Back List
  • Service Hotline 400-8828-621

    Wechat
    Get the latest news

COMPANY
About us
Milestones
Our value
Awards & qualifications
PIDI Standard
NEWS
Exhibitions & Seminars
Company News
Industry dynamics
PRODUCTS
Partners
Applications
APIs
SERVICES

Scan by Wechat
for free samples